Jacobio Pharmaceuticals Group Co., Ltd. (OTCMKTS:JBPHF) Sees Significant Growth in Short Interest

Jacobio Pharmaceuticals Group Co., Ltd. (OTCMKTS:JBPHF) was the target of a significant growth in short interest in September. As of September 15th, there was short interest totaling 1,500 shares. Based on an average daily volume of 300 shares, the days-to-cover ratio is currently 5.0 days.

Jacobio Pharmaceuticals Group Price Performance

JBPHF remained flat at $0.76 during trading hours on Wednesday. 900 shares of the company traded hands, compared to its average volume of 1,180. Jacobio Pharmaceuticals Group has a 1 year low of $0.60 and a 1 year high of $0.76. The stock’s 50-day moving average price is $0.68 and its 200 day moving average price is $0.79.

Jacobio Pharmaceuticals Group Company Profile

Jacobio Pharmaceuticals Group is a clinical-stage biopharmaceutical company focused on discovering and developing targeted therapies for cancer. The company uses proprietary drug-discovery platforms to develop small-molecule medicines aimed at genetically defined or otherwise difficult-to-treat tumors.

Its pipeline has included JAB-21822, also known as glecirasib, an investigational KRAS G12C inhibitor designed to target cancers driven by KRAS G12C mutations. Jacobio has also developed JAB-3312, an SHP2 inhibitor intended for use in oncology, along with other early-stage programs involving targets such as BET proteins and additional cancer-related pathways.

Jacobio conducts research and clinical-development activities primarily in China, with programs and collaborations extending to international markets, including the United States.